The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo‐controlled studies

Desvenlafaxine 50 mg/day significantly improved HAM-D17 total scores by -1.72 points in patients with anxious depression compared to placebo.

• A total of 1873 out of 2706 patients (69%) were classified as having anxious depression based on baseline scores.
• Desvenlafaxine led to significantly higher response and remission rates in both anxious and nonanxious populations compared to placebo.
• The improvement in HAM-D17 total scores was consistent across both anxious and nonanxious groups, with no significant difference in treatment effects based on anxiety levels.
• Treatment-emergent adverse events were reported by 78% of anxious depressed patients receiving desvenlafaxine, compared to 69% in the placebo group.

AI simplified